COMMUNIQUÉS West-GlobeNewswire

MannKind Announces U.S. FDA Accepts for Review its Supplemental Biologics License Application (sBLA) for Inhaled Insulin (Afrezza) in Children and Adolescents Aged 4-17 Years Living with Diabetes
13/10/2025
If approved, it would be the first needle-free insulin option for pediatric patients in 100+ years of insulin therapy sBLA submission based on data from the Phase 3 INHALE-1 study PDUFA target action date of May 29, [...]
ProQR to Participate in Upcoming Investor Conferences in October 2025
13/10/2025
LEIDEN, Netherlands & CAMBRIDGE, Mass., Oct. 13, 2025 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its [...]
Ardelyx Appoints Experienced Finance Executive, Sue Hohenleitner, as Chief Financial Officer
13/10/2025
WALTHAM, Mass., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet [...]
Nexalin Technology Expands Scientific Advisory Board with Appointment of Dr. Robert Rothstein to Support Alzheimer’s and Traumatic Brain Injury Programs
13/10/2025
HOUSTON, TX, Oct. 13, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the “Company” or “Nexalin”), the leader in Deep Intracranial Frequency Stimulation (DIFS™) of the brain, today announced the [...]
Ardelyx to Report Third Quarter 2025 Financial Results on October 30, 2025
13/10/2025
Conference call scheduled for 4:30 p.m. Eastern Time WALTHAM, Mass., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and [...]
Palisade Bio Granted Canadian Patent Covering Composition of Lead Product Candidate PALI-2108
13/10/2025
PALI-2108 is the first and only PDE4 inhibitor designed to target terminal ileum and colon for fibrostenotic Crohn’s disease (FSCD) and ulcerative colitis (UC) to address significant unmet medical needs Carlsbad, CA, [...]
Salarius Pharmaceuticals Regains Compliance with All Nasdaq Listing Requirements
13/10/2025
HOUSTON, Oct. 13, 2025 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX) (Salarius or the Company) announces that on October 10, 2025 the Company received notice from the Nasdaq Stock Market LLC (Nasdaq [...]
Humanitarian Nonprofit Human Appeal USA to Host National Comedy Tour
13/10/2025
Joy and Impact Unleashed as Comedy Tour Funds Critical Relief for Those in Need MISSION VIEJO, Calif., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Humanitarian aid nonprofit, Human Appeal USA , is kicking off their national [...]
Theolytics to Present Ongoing Phase I/IIa OCTOPOD-IV Trial of THEO-260 in Ovarian Cancer at ESMO 2025
13/10/2025
THEO-260 is an oncolytic immunotherapy developed for effective targeting of cancer cells and cancer-associated fibroblasts, whilst inducing immune activation in stromal rich tumours UK clinical trial recruitment is on [...]
ITM Appoints Annette Breunig as Chief People Officer
13/10/2025
Global HR leader to drive ITM’s long-term human resources strategy, support organizational development and corporate growth Garching / Munich, Germany, October 13, 2025 – ITM Isotope Technologies Munich SE (ITM) , a [...]
Aclarion Announces Use of MR Spectroscopy for identifying Biomarkers of Discogenic Pain highlighted at Global Neuroscience Conference
13/10/2025
Panel discussion featured at the International Society of Pain and Neuroscience (ISPN) Annual Meeting in London titled United to Conquer Pain Session Co-Moderator Doug Beall, M.D. underscored that disc chemistry is the [...]
Immuron Q1 FY26 YoY growth
13/10/2025
Sales Highlights (unaudited): Global • Q1 sales AUD$2.0 million up 34% on prior comparative period (pcp) Australia • Q1 sales AUD$1.6 million up 52% on pcp Canada • Q1 sales AUD$0.0 million down 92% on pcp USA • Q1 [...]
CHAPPER healthcare, AscellaHealth’s Global Pharmaceutical Distributor, Celebrates 50 Years of Global Pharmaceutical Excellence
13/10/2025
This milestone marks half a century of innovation, reliability and access to life-saving medicines worldwide WATFORD, United Kingdom and BERWYN, Pa., Oct. 13, 2025 (GLOBE NEWSWIRE) -- CHAPPER healthcare , AscellaHealth’ [...]
Q3 2025 Qualitative Update: Tecan reports mid-single-digit local currency growth in the third quarter and confirms full-year 2025 outlook
13/10/2025
Ad hoc announcement pursuant to Article 53 of the SIX Exchange Regulation Listing Rules Q3 2025 Qualitative Update: Tecan reports mid-single-digit local currency growth in the third quarter and confirms full-year 2025 [...]
Roche data at ESMO 2025 showcase advances in science and cancer care across multiple tumour types
13/10/2025
Basel, 13 October 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it will present more than 30 abstracts across more than 10 cancer types at the European Society for Medical Oncology (ESMO) Congress 2025 [...]
ONWARD Medical Provides Preliminary Q3 2025 Update Highlighting Accelerating ARC-EX Adoption in the United States
13/10/2025
EINDHOVEN, the Netherlands, Oct. 13, 2025 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD – US ADR: ONWRY), the leading neurotechnology company pioneering therapies to restore movement, function, and [...]
Bavarian Nordic shareholders are reminded of expiry of the offer period regarding the takeover offer from consortium consisting of Nordic Capital and Permira
13/10/2025
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION COPENHAGEN, Denmark, [...]
HUTCHMED Highlights FRUSICA-2 Registration Trial Data to be Presented at the 2025 ESMO Congress
13/10/2025
The fruquintinib and sintilimab combination demonstrated significant PFS improvements in advanced renal cell carcinoma patients after progression on first-line therapies HONG KONG and SHANGHAI and FLORHAM PARK, N.J., [...]
Nouscom Presents Positive Phase 2 Results of NOUS-209 Immunotherapy Combined with Pembrolizumab in MSI-H Metastatic Colorectal Cancer Patients Refractory to Anti-PD-1 Therapy, at ESMO 2025
13/10/2025
While immune checkpoint inhibitors (anti-PD-1 +/- anti-CTLA-4) are approved as first line treatment for microsatellite instability-high (MSI-H) metastatic colorectal cancer (mCRC), many patients either don’t respond or [...]

Pages